Anika Therapeutics (ANIK) Change in Account Payables (2010 - 2026)
Anika Therapeutics (ANIK) reported Change in Account Payables of $745000.0 for Q1 2026, up 1485.11% year-over-year from $47000.0 in Q1 2025, and down 15.05% quarter-over-quarter from $877000.0 in Q4 2025.
Anika Therapeutics (ANIK) Change in Account Payables (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has 17 years of Change in Account Payables data on file, last reported at $745000.0 in Q1 2026.
- Change in Account Payables for Q1 2026 came in at $745000.0, up 1485.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $740000.0 (up 125.87% YoY), and the FY2025 annual result was $42000.0, up 101.68% from the prior year.
- Change in Account Payables fell to $745000.0 in Q1 2026 per ANIK's latest filing, from $877000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $1.4 million in Q4 2022 and troughed at -$2.9 million in Q3 2024.
- A 5-year average of $13823.5 and a median of $148000.0 in 2024 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2024 and 2026: Change in Account Payables slumped 911.72% in 2024, then surged 1485.11% in 2026.
- A 5-year view of Change in Account Payables shows it stood at $1.4 million in 2022, then decreased by 8.66% to $1.3 million in 2023, then tumbled by 109.25% to -$121000.0 in 2024, then soared by 824.79% to $877000.0 in 2025, then slipped by 15.05% to $745000.0 in 2026.
- Business Quant data shows ANIK's Change in Account Payables at $745000.0 in Q1 2026, $877000.0 in Q4 2025, and $231000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 62.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 167.64 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 190,000.00 |
| 10 | Anika Therapeutics | 197.89 Mn | 131.10 Mn | 19.00 Mn | 745,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 745,000.00 |
| Mar 31, 2026 | 745,000.00 |
| Dec 31, 2025 | 877,000.00 |
| Dec 31, 2025 | 877,000.00 |
| Sep 30, 2025 | 231,000.00 |
| Sep 30, 2025 | 231,000.00 |
| Jun 30, 2025 | -1.11 Mn |
| Jun 30, 2025 | -1.11 Mn |
| Mar 31, 2025 | 47,000.00 |
| Mar 31, 2025 | 47,000.00 |
| Dec 31, 2024 | -121,000.00 |
| Dec 31, 2024 | -121,000.00 |
| Sep 30, 2024 | -2.93 Mn |
| Sep 30, 2024 | -2.93 Mn |
| Jun 30, 2024 | 148,000.00 |
| Jun 30, 2024 | 148,000.00 |
| Mar 31, 2024 | 401,000.00 |
| Mar 31, 2024 | 401,000.00 |
| Dec 31, 2023 | 1.31 Mn |
| Dec 31, 2023 | 1.31 Mn |